logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10034931 B1

PDFFull Text
Date of Patent:
Jul. 31, 2018

Filed:

Sep. 23, 2014

Use of egfr pathway inhibitors to increase immune responses to antigens

Applicant:

Emory University, Atlanta, GA (US);

Inventors:

Brian P. Pollack, Decatur, GA (US);

Richard W. Compans, Atlanta, GA (US);

Joanna A. Pulit-Penaloza, Atlanta, GA (US);

Ioanna Skountzou, Atlanta, GA (US);

Assignee:

Emory University, Atlanta, GA (US);

Attorney:

Emory Patent Group

Primary Examiner:

Michelle S Horning

Int. Cl.
CPC ...
A61K 39/145 (2006.01); A61K 45/06 (2006.01); A61K 31/517 (2006.01); A61K 9/00 (2006.01); C12N 7/00 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/145 (2013.01); A61K 9/0014 (2013.01); A61K 9/0021 (2013.01); A61K 31/517 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/572 (2013.01); A61K 2039/575 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16163 (2013.01); C12N 2760/16171 (2013.01); C12N 2760/16234 (2013.01);
Abstract

This disclosure relates to using EGFR pathway inhibitors in combination with compositions comprising an antigen to increase, elicit, or improve an antigen or vaccine-induced immune response. In certain embodiments, the EGFR pathway inhibitor is administered under conditions such that memory cells to the antigen are formed in a subject. In certain embodiments, the composition is a vaccine. In certain embodiments, the EGFR pathway inhibitor and vaccine are administered to the skin epidermis or dermis.

Find Patent Forward Citations

Pollack, Brian. (2018). Use of egfr pathway inhibitors to increase immune responses to antigens (U.S. Patent No. 10034931). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10034931

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…